08:00 , Feb 16, 2015 |  BC Week In Review  |  Company News

Napo, Salix Pharmaceuticals Inc. gastrointestinal news

Napo filed an opening brief in the Appellate Division of the Supreme Court of the State of New York (SCSNY) seeking to reverse SCSNY’s decision to narrow the issues for trial by jury in Napo’s...
00:58 , Aug 28, 2014 |  BC Extra  |  Financial News

Napo's Jaguar Animal Health files for IPO

The Jaguar Animal Health Inc. subsidiary of Napo Pharmaceuticals Inc. (San Francisco, Calif.) filed to raise up to $70 million in an IPO on NASDAQ underwritten by BMO Capital Markets; Guggenheim Securities; and Roth Capital...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Company News

Napo, Salix Pharmaceuticals Inc. gastrointestinal news

Salix said a jury in the Supreme Court of the State of New York for the County of New York found that Salix complied with its obligations under a 2008 deal with Napo to commercialize...
08:00 , Jan 13, 2014 |  BioCentury  |  Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer  An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

Napo, Salix gastrointestinal news

Napo said the Supreme Court of the State of New York for the County of New York has scheduled a trial for Feb. 10, 2014, to hear a breach of contract suit Napo filed in...
07:00 , Apr 1, 2013 |  BioCentury  |  Finance

1Q Stock Wrap-Up: Out fast at opening bell

For the second year in a row, biotech put together a strong showing in the first quarter with all market segments gaining ground. The sector was led by mid-caps, which closed up 16%. Large caps...
08:00 , Jan 7, 2013 |  BC Week In Review  |  Clinical News

Fulyzaq crofelemer regulatory update

Salix is engaged in litigation over crofelemer with Napo. In 2011, Napo terminated a 2008 deal giving Salix rights to the drug in North America, Japan and Europe, excluding Liechtenstein, Norway and Switzerland. Napo claimed...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

Buyside View XXI: Sunny side up

Stephen Hansen Senior Writer  A strong crop of early PDUFA dates and a sense that FDA is more navigable have given money managers in the U.S. and Europe a positive outlook for 2013, which they...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

4Q Stock Wrap-Up: Go big or go home

Large cap biotechs were the only market cap segment to end 4Q12 in the black, finishing up 1% to post a 26% gain on the year. Small caps brought up the rear in 4Q, but...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) was off $0.80 to $24.91 Christmas week after FDA approved Juxtapid lomitapide to treat patients with homozygous familial hypercholesterolemia (hoFH). Juxtapid was approved with a REMS and a boxed...